Correlation Between Monopar Therapeutics and Effector Therapeutics
Can any of the company-specific risk be diversified away by investing in both Monopar Therapeutics and Effector Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Monopar Therapeutics and Effector Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Monopar Therapeutics and Effector Therapeutics, you can compare the effects of market volatilities on Monopar Therapeutics and Effector Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Monopar Therapeutics with a short position of Effector Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Monopar Therapeutics and Effector Therapeutics.
Diversification Opportunities for Monopar Therapeutics and Effector Therapeutics
0.31 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Monopar and Effector is 0.31. Overlapping area represents the amount of risk that can be diversified away by holding Monopar Therapeutics and Effector Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Effector Therapeutics and Monopar Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Monopar Therapeutics are associated (or correlated) with Effector Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Effector Therapeutics has no effect on the direction of Monopar Therapeutics i.e., Monopar Therapeutics and Effector Therapeutics go up and down completely randomly.
Pair Corralation between Monopar Therapeutics and Effector Therapeutics
Given the investment horizon of 90 days Monopar Therapeutics is expected to generate 3.06 times more return on investment than Effector Therapeutics. However, Monopar Therapeutics is 3.06 times more volatile than Effector Therapeutics. It trades about 0.05 of its potential returns per unit of risk. Effector Therapeutics is currently generating about -0.07 per unit of risk. If you would invest 1,830 in Monopar Therapeutics on November 2, 2024 and sell it today you would earn a total of 2,420 from holding Monopar Therapeutics or generate 132.24% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 70.85% |
| Values | Daily Returns |
Monopar Therapeutics vs. Effector Therapeutics
Performance |
| Timeline |
| Monopar Therapeutics |
| Effector Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Monopar Therapeutics and Effector Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Monopar Therapeutics and Effector Therapeutics
The main advantage of trading using opposite Monopar Therapeutics and Effector Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Monopar Therapeutics position performs unexpectedly, Effector Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will offset losses from the drop in Effector Therapeutics' long position.| Monopar Therapeutics vs. Anebulo Pharmaceuticals | Monopar Therapeutics vs. Acrivon Therapeutics, Common | Monopar Therapeutics vs. Pmv Pharmaceuticals | Monopar Therapeutics vs. Molecular Partners AG |
| Effector Therapeutics vs. Indaptus Therapeutics | Effector Therapeutics vs. Jasper Therapeutics | Effector Therapeutics vs. RenovoRx | Effector Therapeutics vs. Ensysce Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Complementary Tools
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |